Hypha Labs (FUNI) 10-Q 13 Aug 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document And Entity Information
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,155,550
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Current assets:
Cash	$ 286,365	$ 176,027
Accounts receivable, net	185,829	167,734
Other current assets	98,338	72,690
Deposits	25,647	25,647
Total current assets	596,179	442,098
Fixed assets, net	792,781	957,108
Total Assets	1,388,960	1,399,206
Current liabilities:
Accounts payable	161,917	325,864
Accrued expenses	56,087	58,238
Deferred revenues		525
Total current liabilities	218,004	384,627
Convertible notes payable, net of discounts of $49,747 and $-0- at June 30, 2019 and September 30, 2018, respectively	450,253
Total Liabilities	668,257	384,627
Stockholders' Equity:
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 1,325,942 and 1,425,942 shares issued and outstanding at June 30, 2019 and September 30, 2018, respectively	1,326	1,426
Common stock, $0.001 par value, 250,000,000 and 90,000,000 shares authorized; 48,155,550 and 42,245,364 shares issued and outstanding; at June 30, 2019 and September 30, 2018, respectively	48,156	42,245
Additional paid-in capital	15,224,816	14,121,236
Accumulated (deficit)	(14,553,595)	(13,150,328)
Total Stockholders' Equity	720,703	1,014,579
Total Liabilities and Stockholders' Equity	$ 1,388,960	$ 1,399,206

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Convertible notes payable, discounts	$ 49,747	$ 0
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000	10,000,000
Series A convertible preferred stock, shares issued	1,325,942	1,425,942
Series A convertible preferred stock, shares outstanding	1,325,942	1,425,942
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	90,000,000
Common stock, shares issued	48,155,550	42,245,364
Common stock, shares outstanding	48,155,550	42,245,364

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 652,920	$ 521,772	$ 1,946,590	$ 2,223,630
Cost of sales	424,067	520,888	1,334,217	1,563,518
Gross profit	228,853	884	612,373	660,112
Operating expenses:
General and administrative	431,636	360,689	1,240,612	1,108,202
Professional fees	195,052	228,482	677,299	964,269
Bad debts expense (recoveries)	93,340	(45,200)	143,170	53,041
Total operating expenses	720,028	543,971	2,061,081	2,125,512
Operating loss	(491,175)	(543,087)	(1,448,708)	(1,465,400)
Other income:
Other income	19,750	43,012	92,400	85,912
Interest expense	(18,203)		(46,959)
Total other income	1,547	43,012	45,441	85,912
Net loss	$ (489,628)	$ (500,075)	$ (1,403,267)	$ (1,379,488)
Weighted average number of common shares outstanding - basic and fully diluted	47,934,212	40,374,897	45,509,076	38,237,869
Net loss per share - basic and fully diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated (Deficit) [Member]	Total
Balance at Sep. 30, 2017	$ 1,898	$ 35,027	$ 12,866,984	$ (11,496,671)	$ 1,407,238
Balance, shares at Sep. 30, 2017	1,897,942	35,027,118
Units of common stock and warrants sold for cash		$ 2,159	366,449		368,608
Units of common stock and warrants sold for cash, shares		2,158,934
Common stock issued for services		$ 2,327	450,210		452,537
Common stock issued for services, shares		2,326,855
Common stock options issued for services			439,853		439,853
Conversion of preferred stock to common stock	$ (472)	$ 2,360	(1,888)
Conversion of preferred stock to common stock, shares	(472,000)	2,360,000
Cashless exercise of options and warrants		$ 372	(372)
Cashless exercise of options and warrants, shares		372,457
Net loss				(1,653,657)	(1,653,657)
Balance at Sep. 30, 2018	$ 1,426	$ 42,245	14,121,236	(13,150,328)	1,014,579
Balance, shares at Sep. 30, 2018	1,425,942	42,245,364
Common stock issued for services		$ 1,811	274,204		276,015
Common stock issued for services, shares		1,810,186
Common stock options issued for services			137,412		137,412
Conversion of preferred stock to common stock	$ (100)	$ 500	(400)
Conversion of preferred stock to common stock, shares	(100,000)	500,000
Common stock sold for cash		$ 3,125	621,875		625,000
Common stock sold for cash, shares		3,125,000
Common stock issued in exchange for termination of options		$ 475	(475)
Common stock issued in exchange for termination of options, shares		475,000
Beneficial conversion feature of convertible debts			70,964		70,964
Net loss				(1,403,267)	(1,403,267)
Balance at Jun. 30, 2019	$ 1,326	$ 48,156	$ 15,224,816	$ (14,553,595)	$ 720,703
Balance, shares at Jun. 30, 2019	1,325,942	48,155,550

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (489,628)	$ (500,075)	$ (1,403,267)	$ (1,379,488)	$ (1,653,657)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	93,340	(45,200)	143,170	53,041
Depreciation and amortization expense			194,588	213,225
Stock issued for services			276,015	377,204
Options and warrants granted for services			137,412	438,683
Amortization of debt discounts			21,217
Decrease (increase) in assets:
Accounts receivable			(66,265)	12,705
Other current assets			(25,648)	6,018
Increase (decrease) in liabilities:
Accounts payable			(163,947)	74,240
Accrued expenses			(2,151)	(11,110)
Deferred revenues			(525)	2,775
Net cash used in operating activities			(889,401)	(212,707)
Cash flows from investing activities
Purchase of fixed assets			(30,261)	(194,008)
Advance of note receivable			(95,000)
Net cash used in investing activities			(125,261)	(194,008)
Cash flows from financing activities
Proceeds from convertible notes			500,000
Proceeds from sale of common stock			625,000	268,608
Net cash provided by financing activities			1,125,000	268,608
Net increase (decrease) in cash			110,338	(138,107)
Cash - beginning			176,027	178,177	178,177
Cash - ending	$ 286,365	$ 40,070	286,365	40,070	$ 176,027
Supplemental disclosures:
Interest paid			4,066
Income taxes paid
Non-cash investing and financing activities:
Value of preferred stock converted to common stock			100,000	472,000
Beneficial conversion feature of convertible notes payable			$ 70,964

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	Note 1 – Organization, Basis of Presentation and Significant Accounting Policies Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our business units are described below. Ø Digipath Labs, Inc Ø The National Marijuana News Corp Ø GroSciences, Inc Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019: Name of Entity (1) Jurisdiction of Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, but has not incurred income to date. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. Revenue Recognition Effective October 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of lab testing services through our subsidiary Digipath Labs, Inc., and to a lesser extent, through the sale of advertising through one of our other subsidiaries, TNM News Corp. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the nine months ended June 30, 2019, or the twelve months ended September 30, 2018. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products to licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. The Company also recognizes revenue through our subsidiary, TNM News Corp., which primarily recognizes revenue from advertisements through partnered merchants. Payment for ad revenues are received prior to the distribution of the ad campaign, and the revenues are recognized ratably over the campaign. The Company defers any revenue for which the term of the campaign has not yet been realized. To date, these revenues have not been materially significant. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $14,553,595, and as of June 30, 2019, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2019 and September 30, 2018, respectively: Fair Value Measurements at June 30, 2019 Level 1 Level 2 Level 3 Assets Cash $ 286,365 $ - $ - Total assets 286,365 - - Liabilities Convertible notes payable, net of discounts of $49,747 - - 450,253 Total liabilities - - 450,253 $ 286,365 $ - $ (450,253 ) Fair Value Measurements at September 30, 2018 Level 1 Level 2 Level 3 Assets Cash $ 176,027 $ - $ - Total assets 176,027 - - Liabilities Total liabilities - - - $ 176,027 $ - $ - The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. Level 3 liabilities consist of a total of $500,000 of convertible debentures, net of discounts of $49,747 as of June 30, 2019. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended June 30, 2019 or the year ended September 30, 2018.

Note Receivable

Note Receivable	9 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
Note Receivable	Note 4 – Note Receivable On March 8, 2019 and February 15, 2019, we loaned Big Valley Analytical Labs, Inc. $25,000 and $20,000, respectively. The loans carried interest at an annual rate of 15%, were evidenced by secured demand notes, and were secured by a lien on the borrower’s assets. The principal amount of the loans was subsequently repaid in full on April 1, 2019. On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $95,000. The loans bear interest at an annual rate of 10%, are evidenced by secured demand notes, which are secured by a lien on the borrower’s assets. An allowance for doubtful accounts for the full value of the notes was recognized due to the uncertainty of collectability.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable was $185,829 and $167,734 at June 30, 2019 and September 30, 2018, respectively, net of allowance for doubtful accounts of $63,070 and $14,900 at June 30, 2019 and September 30, 2018, respectively.

Fixed Assets

Fixed Assets	9 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at June 30, 2019 and September 30, 2018: June 30, 2019 September 30, Software $ 123,492 $ 123,492 Office equipment 56,252 54,877 Furniture and fixtures 28,486 28,486 Lab equipment 1,133,730 1,110,930 Leasehold improvements 495,233 489,147 1,837,193 1,806,932 Less: accumulated depreciation (1,044,412 ) (849,824 ) Total $ 792,781 $ 957,108 Depreciation and amortization expense totaled $194,588 and $213,225 for the nine months ended June 30, 2019 and 2018, respectively.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable Convertible notes payable consist of the following at June 30, 2019 and September 30, 2018, respectively: June 30, September 30, On November 8, 2018, the Company received proceeds of $350,000 on a senior secured convertible note that carries an 8% interest rate, which matures on December 31, 2020. The principal and interest are convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. A total of $4,066 of interest was repaid during the nine months ended June 30, 2019. $ 350,000 $ - On November 5, 2018, the Company received proceeds of $150,000 on a senior secured convertible note that carries an 8% interest rate, which matures on December 31, 2020. The principal and interest are convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 150,000 - Total convertible notes payable 500,000 - Less: unamortized debt discounts (49,747 ) - Convertible notes payable $ 450,253 $ - In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $70,964 during the nine months ended June 30, 2019. The discount is amortized on a straight line basis from the dates of issuance until the earlier of the stated redemption date of the debts, as noted above or the actual settlement date. During the nine months ended June 30, 2019, the Company recorded debt amortization expense in the amount of $21,217, attributed to the aforementioned debt discount. All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares. The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $25,742 for the nine months ended June 30, 2019.

Changes in Stockholders' Equity

Changes in Stockholders' Equity	9 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Changes in Stockholders' Equity	Note 8 - Changes in Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”), with the remaining 4,000,000 shares available for designation from time to time by the Board as set forth below. As of June 30, 2019, there were 1,325,942 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which the undesignated shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Each share of Series A Preferred is currently convertible into five shares of common stock. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,325,942 shares of Series A Preferred outstanding at June 30, 2019 are convertible into 6,629,710 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Preferred Stock Conversions On December 31, 2018, a total of 100,000 Series A Preferred shares were converted into 500,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Common stock consists of $0.001 par value, 250,000,000 shares authorized, of which 48,155,550 shares were issued and outstanding as of June 30, 2019. Common Stock Sales On February 7, 2019, the Company sold 1,000,000 shares of its common stock in exchange for proceeds of $200,000. On February 1, 2019, the Company sold 250,000 shares of its common stock in exchange for proceeds of $50,000. On January 31, 2019, the Company sold 625,000 shares of its common stock in exchange for proceeds of $125,000. On January 24, 2019, the Company sold 1,250,000 shares of its common stock in exchange for proceeds of $250,000. Common Stock Issued for Services On June 25, 2019, the Company issued 300,000 shares of common stock to a consultant for business development services to be performed from May 1, 2019 through October 31, 2019. The fair value of the common stock was $58,500 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the requisite service period. On June 25, 2019, the Company issued 41,667 shares of common stock to its President and CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On June 25, 2019, the Company issued 104,167 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On May 25, 2019, a total of 50,000 shares of common stock were issued to a consultant that was engaged to assist the Company with acquisition activities. The fair value of the common stock was $8,030 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On April 25, 2019, a total of 50,000 shares of common stock were issued to a consultant that was engaged to assist the Company with acquisition activities. The fair value of the common stock was $9,500 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 29, 2019, the Company issued 475,000 shares of common stock to the estate of our former CEO in exchange for the cancellation of 4,750,000 common stock options. The aggregate fair value of the options exceeded the fair value of the common stock at issuance, therefore there was no additional expense as a result of the modification of the equity awards. On March 25, 2019, the Company issued 29,268 shares of common stock to its President and CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 25, 2019, the Company issued 73,171 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 25, 2019, a total of 50,000 shares of common stock were issued to a consultant that was engaged to assist the Company with acquisition activities. The fair value of the common stock was $10,250 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On February 25, 2019, a total of 50,000 shares of common stock were issued to a consultant that was engaged to assist the Company with acquisition activities. The fair value of the common stock was $12,300 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On January 25, 2019, a total of 50,000 shares of common stock were issued to a consultant that was engaged to assist the Company with acquisition activities. The fair value of the common stock was $10,500 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2018, the Company issued 46,261 shares of common stock to its President and CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2018, the Company issued 115,652 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $19,455 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On November 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $24,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On October 30, 2018, the Company issued 400,000 shares of common stock to another consultant for business development services to be performed from November 1, 2018 through April 30, 2019. The fair value of the common stock was $54,120 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the requisite service period. On October 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $23,250 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. Amortization of Stock-Based Compensation A total of $22,110 of stock-based compensation expense was recognized during the nine months ended June 30, 2019 as a result of the issuance of 200,000 shares of common stock to one of our directors, Bruce Raben, on September 12, 2018, as amortized over the requisite service period. As of June 30, 2019, a total of $7,452 of unamortized expenses are expected to be expensed during the remaining fiscal year ended September 30, 2019. A total of $19,500 of stock-based compensation expense was recognized during the nine months ended June 30, 2019 as a result of the issuance of 300,000 shares of common stock to a consultant on June 25, 2019, as amortized over the requisite service period. As of June 30, 2019, a total of $39,000 of unamortized expenses are expected to be expensed during the remaining requisite service period. A total of $137,412 of stock-based compensation expense was recognized from the amortization of options over their vesting period during the nine months ended June 30, 2019.

Common Stock Options

Common Stock Options	9 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Common Stock Options	Note 9 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. A total of 5,105,000 options were outstanding as of June 30, 2019. During the nine months ended June 30, 2019, options to purchase an aggregate total of 27,500 shares of common stock at a weighted average exercise price of $0.26 per share expired. Options Issued to Officers and Directors for Services On January 7, 2019, we granted options to purchase 500,000 shares of common stock as compensation for services to our Chief Science Officer. The options vest immediately as to 125,000 shares and as to an additional 125,000 shares on each of April 7, 2019, July 7, 2019, and October 7, 2019, and are exercisable for a ten-year period at an exercise price of $0.13 per share, based on the most recent closing stock price. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1019, was $50,934. The options are being expensed over the vesting period, resulting in $32,463 of stock-based compensation expense during the nine months ended June 30, 2019. As of June 30, 2019, a total of $18,471 of unamortized expenses are expected to be expensed over the vesting period. On January 7, 2019, we granted options to purchase 500,000 shares of common stock as compensation for services to Bruce Raben, one of our directors. The options vest immediately as to 125,000 shares and as to an additional 125,000 shares on each of April 7, 2019, July 7, 2019, and October 7, 2019, and are exercisable for a ten-year period at an exercise price of $0.13 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1019, was $50,934. The options are being expensed over the vesting period, resulting in $32,463 of stock-based compensation expense during the nine months ended June 30, 2019. As of June 30, 2019, a total of $18,471 of unamortized expenses are expected to be expensed over the vesting period. Options Exchanged for Common Stock On March 29, 2019, the Company issued 475,000 shares of common stock to the estate of our former CEO in exchange for the cancellation of 4,750,000 common stock options. The aggregate fair value of the options exceeded the fair value of the common stock at issuance, therefore there was no additional expense as a result of the modification of the equity awards. Re-Priced Options Issued to Officers and Directors for Services On January 7, 2019, the board amended the following options to reduce their exercise price to $0.13 per share, based on the most recent closing stock price. All other terms were unchanged. The modification of these equity awards resulted in an additional expense of $36,764. Original Recipient’s Option # of Term Original New Grant Date Name Type Options In Mos. Exercise $ Exercise $ 6/1/2015 Cindy Orser NSO Options 200,000 120 $ 0.40 $ 0.13 6/19/2015 Todd Peterson ISO Options 100,000 120 $ 0.33 $ 0.13 6/21/2016 Todd Denkin ISO Options 2,500,000 120 $ 0.20 $ 0.13 11/29/2017 Cindy Orser NSO Options 100,000 120 $ 0.27 $ 0.13 12/22/2017 Todd Denkin ISO Options 500,000 120 $ 0.27 $ 0.13 3,400,000 Options Issued to Employees for Services On December 25, 2018, we granted fully vested options to purchase an aggregate of 345,000 shares of common stock as compensation for services to a total of fourteen of our employees. The options are exercisable over a ten-year period at an exercise price of $0.13 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1017, was $35,078. The options are being expensed over the vesting period, resulting in $17,971 of stock-based compensation expense during the nine months ended June 30, 2019. As of June 30, 2019, a total of $17,107 of unamortized expenses are expected to be expensed over the vesting period.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Common Stock Warrants	Note 10 – Common Stock Warrants Warrants to purchase a total of 3,417,126 shares of common stock were outstanding as of June 30, 2019. On various dates from December 21, 2018 to May 2, 2019, warrants to purchase an aggregate of 2,933,336 shares of common stock at $0.30 per share expired, and on November 23, 2018, warrants to purchase another 100,000 shares of common stock at $0.40 per share expired.

Other Income

Other Income	9 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
Other Income	Note 11 – Other Income Other income for the nine months ended June 30, 2019 and 2018 consisted of the following: June 30, 2019 2018 Settlement income on note receivable $ 30,000 $ - Rental income on subleases 62,400 57,600 Restitution income - 28,312 $ 92,400 $ 85,912 On December 1, 2018, we received $30,000 as full settlement of a Note dated December 17, 2014, consisting of $250,000 of principal and approximately $58,125 of unpaid interest that was previously written off as uncollectible.

Income Tax

Income Tax	9 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax	Note 12 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the nine months ended June 30, 2019 and the year ended September 30, 2018, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2019, the Company had approximately $8,900,000 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2019 and September 30, 2018, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events There were no subsequent events to report.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019: Name of Entity (1) Jurisdiction of Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, but has not incurred income to date. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Revenue Recognition	Revenue Recognition Effective October 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of lab testing services through our subsidiary Digipath Labs, Inc., and to a lesser extent, through the sale of advertising through one of our other subsidiaries, TNM News Corp. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the nine months ended June 30, 2019, or the twelve months ended September 30, 2018. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products to licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. The Company also recognizes revenue through our subsidiary, TNM News Corp., which primarily recognizes revenue from advertisements through partnered merchants. Payment for ad revenues are received prior to the distribution of the ad campaign, and the revenues are recognized ratably over the campaign. The Company defers any revenue for which the term of the campaign has not yet been realized. To date, these revenues have not been materially significant.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019: Name of Entity (1) Jurisdiction of Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, but has not incurred income to date. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2019 and September 30, 2018, respectively: Fair Value Measurements at June 30, 2019 Level 1 Level 2 Level 3 Assets Cash $ 286,365 $ - $ - Total assets 286,365 - - Liabilities Convertible notes payable, net of discounts of $49,747 - - 450,253 Total liabilities - - 450,253 $ 286,365 $ - $ (450,253 ) Fair Value Measurements at September 30, 2018 Level 1 Level 2 Level 3 Assets Cash $ 176,027 $ - $ - Total assets 176,027 - - Liabilities Total liabilities - - - $ 176,027 $ - $ -

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at June 30, 2019 and September 30, 2018: June 30, 2019 September 30, Software $ 123,492 $ 123,492 Office equipment 56,252 54,877 Furniture and fixtures 28,486 28,486 Lab equipment 1,133,730 1,110,930 Leasehold improvements 495,233 489,147 1,837,193 1,806,932 Less: accumulated depreciation (1,044,412 ) (849,824 ) Total $ 792,781 $ 957,108

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Note 7 – Convertible Notes Payable Convertible notes payable consist of the following at June 30, 2019 and September 30, 2018, respectively: June 30, September 30, On November 8, 2018, the Company received proceeds of $350,000 on a senior secured convertible note that carries an 8% interest rate, which matures on December 31, 2020. The principal and interest are convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. A total of $4,066 of interest was repaid during the nine months ended June 30, 2019. $ 350,000 $ - On November 5, 2018, the Company received proceeds of $150,000 on a senior secured convertible note that carries an 8% interest rate, which matures on December 31, 2020. The principal and interest are convertible into shares of common stock at the discretion of the note holder at a fixed conversion price of $0.14 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc. 150,000 - Total convertible notes payable 500,000 - Less: unamortized debt discounts (49,747 ) - Convertible notes payable $ 450,253 $ -

Common Stock Options (Tables)

Common Stock Options (Tables)	9 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Re-Priced Options Issued to Officers and Directors for Services	Original Recipient’s Option # of Term Original New Grant Date Name Type Options In Mos. Exercise $ Exercise $ 6/1/2015 Cindy Orser NSO Options 200,000 120 $ 0.40 $ 0.13 6/19/2015 Todd Peterson ISO Options 100,000 120 $ 0.33 $ 0.13 6/21/2016 Todd Denkin ISO Options 2,500,000 120 $ 0.20 $ 0.13 11/29/2017 Cindy Orser NSO Options 100,000 120 $ 0.27 $ 0.13 12/22/2017 Todd Denkin ISO Options 500,000 120 $ 0.27 $ 0.13 3,400,000

Other Income (Tables)

Other Income (Tables)	9 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
Schedule of Other Income	Other income for the nine months ended June 30, 2019 and 2018 consisted of the following: June 30, 2019 2018 Settlement income on note receivable $ 30,000 $ - Rental income on subleases 62,400 57,600 Restitution income - 28,312 $ 92,400 $ 85,912

Organization, Basis of Presen_4

Organization, Basis of Presentation and Significant Accounting Policies (Details Narrative)	9 Months Ended
	Jun. 30, 2019Segment
Accounting Policies [Abstract]
Number of reportable segment	1

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details) - Entities Under Common Control and Ownership [Member]	9 Months Ended
	Jun. 30, 2019
Name of Entity	Digipath, Inc.	[1],[2]
Jurisdiction of Incorporation	Nevada
Relationship	Parent	[2]
Name of Entity	Digipath Labs, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	TNM News, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	GroSciences, Inc.	[1],[3]
Jurisdiction of Incorporation	Colorado
Relationship	Subsidiary	[3]
Name of Entity	Digipath Labs S.A.S.	[1],[4]
Jurisdiction of Incorporation	Colombia	[4]
Relationship	Subsidiary	[4]
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.
[3]	Commenced operations during the first fiscal quarter of 2019, but has not incurred income to date.
[4]	Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 14,553,595	$ 13,150,328

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Convertible debentures, current	$ 500,000
Convertible debt, discount	$ 49,747

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Convertible notes payable, net of discounts of $49,747	$ 450,253
Level 1 [Member]
Cash	286,365	176,027
Total assets	286,365	176,027
Convertible notes payable, net of discounts of $49,747
Total liabilities
Total	286,365	176,027
Level 2 [Member]
Cash
Total assets
Convertible notes payable, net of discounts of $49,747
Total liabilities
Total
Level 3 [Member]
Cash
Total assets
Convertible notes payable, net of discounts of $49,747	450,253
Total liabilities	450,253
Total	$ (450,253)

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Convertible notes payable, discounts	$ 49,747

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	Jun. 13, 2019	Mar. 08, 2019	Feb. 15, 2019
Big Valley Analytical Labs, Inc [Member]
Loan received from related party		$ 25,000	$ 20,000
Note bearing interest rate		15.00%	15.00%
Northwest Analytical Labs, Inc. [Member] | Various Dates Between December 28, 2018 and June 13, 2019 [Member]
Loan received from related party	$ 95,000
Note bearing interest rate	10.00%

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Receivables [Abstract]
Accounts receivable	$ 185,829	$ 167,734
Allowance for doubtful accounts	$ 63,070	$ 14,900

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 194,588	$ 213,225

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Software	$ 123,492	$ 123,492
Office equipment	56,252	54,877
Furniture and fixtures	28,486	28,486
Lab equipment	1,133,730	1,110,930
Leasehold improvements	495,233	489,147
Fixed assets, gross	1,837,193	1,806,932
Less: accumulated depreciation	(1,044,412)	(849,824)
Total	$ 792,781	$ 957,108

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2018
Total debt discount	$ 49,747
Debt amortization expense	21,217
Convertible notes interest expense	$ 25,742
Maximum Share Amount [Member]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Total debt discount	$ 70,964

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Total convertible notes payable	$ 500,000
Less: unamortized debt discounts	(49,747)
Convertible notes payable	450,253
Convertible Notes Payable One [Member]
Total convertible notes payable	350,000
Convertible Notes Payable Two [Member]
Total convertible notes payable	$ 150,000

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Nov. 08, 2018	Nov. 05, 2018	Jun. 30, 2019	Jun. 30, 2018
Proceeds from convertible note			$ 500,000
Senior Secured Convertible Note [Member]
Proceeds from convertible note	$ 350,000	$ 150,000
Debt carries interest rate	8.00%	8.00%
Debt maturity date	Dec. 31, 2020	Dec. 31, 2020
Conversion price per share	$ 0.14	$ 0.14
Interest repaid			$ 4,066

Changes in Stockholders' Equi_2

Changes in Stockholders' Equity (Details Narrative) - USD ($)	Jun. 25, 2019	May 25, 2019	Apr. 25, 2019	Mar. 29, 2019	Mar. 25, 2019	Feb. 25, 2019	Feb. 07, 2019	Feb. 01, 2019	Jan. 31, 2019	Jan. 25, 2019	Jan. 24, 2019	Dec. 31, 2018	Dec. 25, 2018	Nov. 25, 2018	Oct. 30, 2018	Oct. 25, 2018	Sep. 12, 2018	Jun. 30, 2019	Sep. 30, 2018
Preferred stock, shares authorized																		10,000,000	10,000,000
Preferred stock, par value																		$ 0.001	$ 0.001
Preferred stock, shares issued																		1,325,942	1,425,942
Preferred stock, shares outstanding																		1,325,942	1,425,942
Common stock par value																		$ 0.001	$ 0.001
Common stock authorized																		250,000,000	90,000,000
Common stock, shares issued																		48,155,550	42,245,364
Common Stock, shares outstanding																		48,155,550	42,245,364
Number of common stock shares sold							1,000,000	250,000	625,000		1,250,000
Proceeds from sale of common stock							$ 200,000	$ 50,000	$ 125,000		$ 250,000
Common stock issued for services, fair value																		$ 276,015	$ 452,537
Stock-based compensation expense																		$ 137,412
Common Stock [Member]
Number of common stock issued for services																		1,810,186	2,326,855
Common stock issued for services, fair value																		$ 1,811	$ 2,327
President and Chief Executive Officer [Member]
Number of common stock issued for services	41,667				29,268								46,261
Common stock issued for services, fair value	$ 6,000				$ 6,000								$ 6,000
Chief Financial Officer [Member]
Number of common stock issued for services	104,167				73,171								115,652
Common stock issued for services, fair value	$ 15,000				$ 15,000								$ 15,000
Consultant [Member]
Number of common stock issued for services		50,000	50,000		50,000	50,000				50,000
Common stock issued for services, fair value		$ 8,030	$ 9,500		$ 10,250	$ 12,300				$ 10,500
Consultant [Member] | Common Stock [Member]
Number of common stock issued for services	300,000
Stock-based compensation expense																		19,500
Unamortized expenses																		39,000
Chief Executive Officer [Member]
Number of common stock issued for services				475,000
Number of common stock options, cancelled				4,750,000
Bruce Raben [Member] | Common Stock [Member]
Number of common stock issued for services																	200,000
Stock-based compensation expense																		22,110
Unamortized expenses																		$ 7,452
Consultants [Member]
Number of common stock issued for services	300,000
Common stock issued for services, fair value	$ 58,500
Three Consultants [Member]
Number of common stock issued for services													150,000	150,000		150,000
Common stock issued for services, fair value													$ 19,455	$ 24,000		$ 23,250
Another Consultants [Member]
Number of common stock issued for services															400,000
Common stock issued for services, fair value															$ 54,120
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized																		6,000,000
Preferred stock, shares designated remaining																		4,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued																		1,325,942
Preferred stock, shares outstanding																		1,325,942
Preferred stock convertible into common stock shares																		6,629,710
Percentage of equity beneficial ownership																		4.99%
Stock conversion, shares converted												100,000
Stock conversion, shares issued												500,000

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)	Mar. 29, 2019	Jan. 07, 2019	Dec. 25, 2018	Jun. 21, 2016	Jun. 30, 2019
Number of options outstanding					5,105,000
Number of options granted to purchase shares of common stock		3,400,000
Fourteen Employees [Member]
Options exercisable period			10 years
Number of options vested			345,000
Options exercise price per share			$ 0.13
Volatility rate			107.00%
Call option value			$ 0.1017
Fair value of stock options			$ 35,078
Stock based compensation expense					$ 17,971
Unamortized expenses expected to be expensed					17,107
Chief Science Officer [Member]
Options exercisable period		10 years
Number of options granted to purchase shares of common stock		500,000
Number of options vested		125,000
Options exercise price per share		$ 0.13
Volatility rate		107.00%
Call option value		$ 0.1019
Fair value of stock options		$ 50,934
Stock based compensation expense					32,463
Unamortized expenses expected to be expensed					$ 18,471
Chief Science Officer [Member] | April 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Chief Science Officer [Member] | July 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Chief Science Officer [Member] | October 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Bruce Raben [Member]
Options exercisable period		10 years
Number of options granted to purchase shares of common stock		500,000
Number of options vested		125,000
Options exercise price per share		$ 0.13
Volatility rate		107.00%
Call option value		$ 0.1019
Fair value of stock options		$ 50,934
Stock based compensation expense					$ 32,463
Unamortized expenses expected to be expensed					$ 18,471
Bruce Raben [Member] | April 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Bruce Raben [Member] | July 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Bruce Raben [Member] | October 7, 2019 [Member]
Options exercisable period					10 years
Number of options vested					125,000
Options exercise price per share					$ 0.13
Chief Executive Officer [Member]
Number of common stock shares issued	475,000
Exchange for the cancellation of common stock options	4,750,000
Officers and Directors [Member]
Options exercise price per share		$ 0.13
Option plan expense		$ 36,764
Common Stock [Member]
Common stock options purchased during period					27,500
Weighted average exercise price per share expired					$ 0.26
Number of common stock shares issued					3,125,000
2012 Stock Incentive Plan [Member]
Number of shares issued under stock plan				11,500,000
Options exercisable period				10 years

Common Stock Options - Schedule

Common Stock Options - Schedule of Re-Priced Options Issued to Officers and Directors for Services (Details)	Jan. 07, 2019$ / sharesshares
Number of Options | shares	3,400,000
Cindy Orser [Member] | Original Grant Date 6/1/2015 [Member]
Option Type	NSO Options
Number of Options | shares	200,000
Term IN MOS	120 months
Original Exercise price	$ 0.40
New Exercise Price	$ 0.13
Cindy Orser [Member] | Original Grant Date 11/29/2017 [Member]
Option Type	NSO Options
Number of Options | shares	100,000
Term IN MOS	120 months
Original Exercise price	$ 0.27
New Exercise Price	$ 0.13
Todd Peterson [Member] | Original Grant Date 6/19/2015 [Member]
Option Type	ISO Options
Number of Options | shares	100,000
Term IN MOS	120 months
Original Exercise price	$ 0.33
New Exercise Price	$ 0.13
Todd Denkin [Member] | Original Grant Date 6/21/2016 [Member]
Option Type	ISO Options
Number of Options | shares	2,500,000
Term IN MOS	120 months
Original Exercise price	$ 0.20
New Exercise Price	$ 0.13
Todd Denkin [Member] | Original Grant Date 12/22/2017 [Member]
Option Type	ISO Options
Number of Options | shares	500,000
Term IN MOS	120 months
Original Exercise price	$ 0.27
New Exercise Price	$ 0.13

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - $ / shares	Jun. 30, 2019	Nov. 23, 2018
Number of warrant to purchase of common stock shares	3,417,126	100,000
Warrants exercise price per share		$ 0.40
Various Dates From December 21, 2018 and May 2, 2019 [Member]
Number of warrant to purchase of common stock shares	2,933,336
Warrants exercise price per share	$ 0.30

Other Income (Details Narrative

Other Income (Details Narrative) - USD ($)	Dec. 01, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Income and Expenses [Abstract]
Proceeds from repayments of notes payable	$ 30,000	$ (30,000)
Debt instrument principal amount	250,000
Unpaid interest	$ 58,125

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Details) - USD ($)	Dec. 01, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Income and Expenses [Abstract]
Settlement income on note receivable	$ (30,000)	$ 30,000
Rental income on subleases		62,400	57,600
Restitution income			28,312
Other income		$ 92,400	$ 85,912

Income Tax (Details Narrative)

Income Tax (Details Narrative)	9 Months Ended
	Jun. 30, 2019USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 8,900,000
Operating loss expiration year	2031